Characterization of response to atezolizumab + bevacizumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Characterization of response to atezolizumab + bevacizumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial

Published:2021-06-29 Issue:16 Volume:10 Page:5437-5447
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Salem Riad¹^ORCID,Li Daneng²,Sommer Nicolas³,Hernandez Sairy³,Verret Wendy³,Ding Beiying³,Lencioni Riccardo⁴⁵^ORCID

Affiliation:

1. Department of Radiology Feinberg School of Medicine Northwestern University Evanston IL USA

2. Department of Medical Oncology City of Hope Comprehensive Cancer Center and Beckman Research Institute Duarte CA USA

3. Genentech, Inc South San Francisco CA USA

4. Department of Radiology University of Pisa School of Medicine Pisa Italy

5. Miami Cancer Institute Miami FL USA

Publisher

Wiley

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.4090

Reference27 articles.

1. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

2. New Guidelines to Evaluate the Response to Treatment in Solid Tumors

3. Update in methodology and conduct of cancer clinical trials

4. Timing and extent of response in colorectal cancer: critical review of current data and implication for future trials

5. Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC)

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The current status and future of targeted-immune combination for hepatocellular carcinoma;Frontiers in Immunology;2024-08-05

2. Recent Advances in Liver Transplantation for Hepatocellular Carcinoma;Current Treatment Options in Oncology;2024-08-01

3. RECIST 1.1, mRECIST, and Choi criteria for evaluating treatment response and survival outcomes in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab;European Radiology;2024-07-30

4. Tumor response assessment in hepatocellular carcinoma treated with immunotherapy: imaging biomarkers for clinical decision-making;European Radiology;2024-07-20

5. Evolution of Systemic Treatment for Hepatocellular Carcinoma: Changing Treatment Strategies and Concepts;Cancers;2024-06-28

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3